5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer

Jianming Shao,Yitian Xu,Randall J. Olsen,Saro Kasparian,Kai Sun,Sunil Mathur,Jun Zhang,Chuan He,Shu-Hsia Chen,Eric H. Bernicker,Zejuan Li
DOI: https://doi.org/10.3390/cells13080715
IF: 6
2024-04-20
Cells
Abstract:Immune checkpoint inhibitors (ICIs) drastically improve therapeutic outcomes for lung cancer, but accurately predicting individual patient responses to ICIs remains a challenge. We performed the genome-wide profiling of 5-hydroxymethylcytosine (5hmC) in 85 plasma cell-free DNA (cfDNA) samples from lung cancer patients and developed a 5hmC signature that was significantly associated with progression-free survival (PFS). We built a 5hmC predictive model to quantify the 5hmC level and validated the model in the validation, test, and control sets. Low weighted predictive scores (wp-scores) were significantly associated with a longer PFS compared to high wp-scores in the validation [median 7.6 versus 1.8 months; p = 0.0012; hazard ratio (HR) 0.12; 95% confidence interval (CI), 0.03–0.54] and test (median 14.9 versus 3.3 months; p = 0.00074; HR 0.10; 95% CI, 0.02–0.50) sets. Objective response rates in patients with a low or high wp-score were 75.0% (95% CI, 42.8–94.5%) versus 0.0% (95% CI, 0.0–60.2%) in the validation set (p = 0.019) and 80.0% (95% CI, 44.4–97.5%) versus 0.0% (95% CI, 0.0–36.9%) in the test set (p = 0.0011). The wp-scores were also significantly associated with PFS in patients receiving single-agent ICI treatment (p < 0.05). In addition, the 5hmC predictive signature demonstrated superior predictive capability to tumor programmed death-ligand 1 and specificity to ICI treatment response prediction. Moreover, we identified novel 5hmC-associated genes and signaling pathways integral to ICI treatment response in lung cancer. This study provides proof-of-concept evidence that the cfDNA 5hmC signature is a robust biomarker for predicting ICI treatment response in lung cancer.
cell biology
What problem does this paper attempt to address?
### The problems the paper attempts to solve The key problem this paper attempts to solve is **how to accurately predict the response of lung cancer patients to immune checkpoint inhibitor (ICI) treatment**. Although ICIs have shown great potential in improving the treatment outcomes of lung cancer patients, there is still a lack of effective biomarkers to accurately predict the response of individual patients to this treatment at present. This results in many patients receiving ICI treatment may not benefit from it, and may even suffer from unnecessary side effects and economic burdens. Specifically, the paper addresses this problem in the following aspects: 1. **Developing 5 - hydroxymethylcytosine (5hmC) features**: - Researchers conducted a genome - wide 5hmC profiling of plasma cell - free DNA (cfDNA) from 85 lung cancer patients and discovered a 16 - gene 5hmC feature that was significantly associated with progression - free survival (PFS). - Based on this feature, they established a prediction model and calculated the weighted prediction score (wp - score) for each sample. 2. **Validating the predictive ability of 5hmC features**: - This model showed good predictive performance in the training set, validation set, test set, and control set. A low wp - score was significantly associated with a longer PFS, while a high wp - score was associated with a shorter PFS. - In addition, the objective response rate (ORR) of patients with a low wp - score was significantly higher than that of patients with a high wp - score. 3. **Comparing 5hmC features with existing biomarkers**: - Compared with tumor PD - L1 expression, 5hmC features have higher accuracy in predicting the response to ICI treatment. PD - L1 expression has no significant association in predicting PFS, overall survival (OS), or ORR. 4. **Exploring the specificity of 5hmC features**: - The study found that 5hmC features are only effective in predicting the response to ICI treatment, and have no significant association in predicting the effects of other treatment methods, indicating its specificity. 5. **Molecular mechanism analysis**: - By analyzing the genes and signaling pathways associated with abnormal 5hmC levels, researchers found that these genes are mainly enriched in signaling pathways related to immune function, further revealing the potential mechanism of 5hmC in the response to ICI treatment. In conclusion, this paper provides a new and more accurate biomarker for predicting the response of lung cancer patients to ICI treatment by developing and validating 5hmC features, thereby helping to optimize treatment regimens and reduce unnecessary side effects and economic burdens.